Kalaris Therapeutics Inc

KLRSNASDAQHealthcare● Active

$4.20

+$0.03(+0.65%)

Market Cap$78500825

P/E Ratio—

52W High$11.88

52W Low$2.14

Avg Volume82K

Open$4.26

Beta0.14

Revenue Financials Earnings

Kalaris Therapeutics Inc (KLRS) Revenue

Annual & quarterly revenue history · segment & region breakdown

KLRS · revenue · updated Jun 10, 2026

Core revenue metrics

Trailing 12 months

Kalaris Therapeutics Inc trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue

$0.00B

4-quarter sum · USD

YoY growth

+0.00%

vs FY —

Price / sales

—

mktCap ÷ TTM rev

Revenue per day

—

Est. TTM ÷ 365

Revenue / employee

$0K

14 employees

—

5Y CAGR

—

Fiscal year end

Dec 31

Currency

USD · GAAP

Filing

10-K / 10-Q

Source: FMP · Kalaris Therapeutics Inc SEC filings · GAAPUpdated: 2026-06-10

Revenue trend

– · Annual

YoY revenue growth %

revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year end	Revenue	Change	Growth

KLRS revenue by year · KLRS revenue history · KLRS annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Kalaris Therapeutics Inc receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Kalaris Therapeutics Inc reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Kalaris Therapeutics Inc's 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Price history Financial statements Forecast

Frequently asked questions

KLRS revenue · 4 questions

KLRS's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

KLRS revenueKLRS annual revenuewhat is KLRS revenueKLRS TTM revenue

▸ Source: FMP · Kalaris Therapeutics Inc SEC filings · GAAP · Kalaris Therapeutics Inc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026